Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Seeking Alpha

19 Jun 2026, 19:49 UTC · 1d ago

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Alkermes reports positive phase 2 data for alixorexton in narcolepsy type 2. — Positive clinical trial data for a new pipeline candidate typically drives significant valuation increases for biotech firms.
+0.60
2
The acquisition of Avadel Pharmaceuticals is considered accretive to Alkermes. — Accretive acquisitions improve earnings per share and indicate efficient capital allocation.
+0.40
3
LUMRYZ has delivered robust early sales and revenue momentum following its acquisition. — Strong commercial uptake of a new product validates the company's growth thesis and immediate revenue stream.
+0.40
4
Alkermes is currently conducting phase 3 Brilliance Studies to further its pipeline. — Ongoing phase 3 trials represent future potential catalysts but carry inherent execution risk.

6 related stories

Accesswire
1d ago
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
- biotech
- clinical trials
- drug development
Read

Alkermes: 'Buy' On Avadel… — ALKS +1.00 | NewsImpactScreener

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

What matters in this story

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

What matters in this story

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

AbbVie would gain an experimental eczema drug by buying biotech: report

3 Penny Stocks Under $5 Backed by Real Revenue Growth

Medicus Pharma advances Teverelix in prostate cancer - ICYMI

Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

What matters in this story

Next reads from the same story arc

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

What matters in this story

Next reads from the same story arc

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

AbbVie would gain an experimental eczema drug by buying biotech: report

3 Penny Stocks Under $5 Backed by Real Revenue Growth

Medicus Pharma advances Teverelix in prostate cancer - ICYMI

Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC